Acorda Therapeutics (NASDAQ:ACOR) Trading 2.9% Higher

Acorda Therapeutics Inc (NASDAQ:ACOR) traded up 2.9% during trading on Friday . The company traded as high as $7.88 and last traded at $7.82. 19,825 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 885,857 shares. The stock had previously closed at $7.60.

A number of research analysts recently commented on the company. Wedbush assumed coverage on Acorda Therapeutics in a research report on Wednesday, May 22nd. They issued a “neutral” rating and a $12.00 price target on the stock. BidaskClub upgraded Acorda Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, February 28th. Zacks Investment Research cut Acorda Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, March 18th. Finally, Oppenheimer restated a “hold” rating on shares of Acorda Therapeutics in a research report on Tuesday, March 19th. Four research analysts have rated the stock with a sell rating, six have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Acorda Therapeutics presently has an average rating of “Hold” and a consensus target price of $19.30.

The company has a debt-to-equity ratio of 0.66, a current ratio of 4.30 and a quick ratio of 3.97. The firm has a market capitalization of $365.79 million, a P/E ratio of 4.14 and a beta of 1.37.

Acorda Therapeutics (NASDAQ:ACOR) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.07) by $0.51. Acorda Therapeutics had a positive return on equity of 9.34% and a negative net margin of 1.40%. The company had revenue of $44.14 million for the quarter, compared to the consensus estimate of $35.14 million. During the same period in the previous year, the business earned $0.14 earnings per share. Acorda Therapeutics’s quarterly revenue was down 58.4% compared to the same quarter last year. On average, equities analysts predict that Acorda Therapeutics Inc will post -4.11 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of Montreal Can lifted its stake in Acorda Therapeutics by 100.8% in the 4th quarter. Bank of Montreal Can now owns 2,116 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 1,062 shares in the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in Acorda Therapeutics in the 4th quarter valued at approximately $44,000. Financial Gravity Wealth Inc. acquired a new position in shares of Acorda Therapeutics in the first quarter worth $44,000. NumerixS Investment Technologies Inc acquired a new position in shares of Acorda Therapeutics in the fourth quarter worth $77,000. Finally, Piedmont Investment Advisors Inc. acquired a new position in shares of Acorda Therapeutics in the first quarter worth $134,000.

COPYRIGHT VIOLATION NOTICE: This story was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at

Acorda Therapeutics Company Profile (NASDAQ:ACOR)

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.

Featured Article: Fibonacci Channel

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with's FREE daily email newsletter.